Outcome of Board meeting held today i.e May 28, 2026 through video conferencing at 02.30 P.M for approval of Audited Financial Results for the half year and financial year ended March 31, 2026
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Clinitech Laboratory Ltd reported audited standalone revenue of ₹947.50 lakhs for FY26, up 15% from ₹823.49 lakhs in FY25. Consolidated revenue came in at ₹949.12 lakhs. Profit after tax grew modestly by 7% to ₹42.25 lakhs (standalone) and ₹41.79 lakhs (consolidated). The company generated negative operating cash flows of ₹89.55 lakhs in FY26 (vs ₹87.87 lakhs in FY25), indicating ongoing cash burn despite profitability. Long-term borrowings increased to ₹35.76 lakhs (standalone) from nil previously. The statutory auditors Kale Malde & Co issued an unmodified opinion on both standalone and consolidated financial statements. The company also noted related party transactions for FY26-27. IPO proceeds of ₹578.30 lakhs were partially utilised with ₹50 lakhs still unutilised.
Revenue growth of 15% is positive but below strong growth thresholds; negative operating cash flow is a concern for shareholders as profitability has not translated into cash generation, and increased debt raises leverage risk.